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Objective: To assess the cost effectiveness of primary angioplasty, compared with medical management with
thrombolytic drugs, to achieve reperfusion after acute myocardial infarction (AMI) from the perspective of the
UK NHS.
Design: Bayesian evidence synthesis and decision analytic model.
Methods: A systematic review was conducted and Bayesian statistical methods used to synthesise evidence
from 22 randomised control trials. Resource utilisation was based on UK registry data, published literature
and national databases, with unit costs taken from routine NHS sources and published literature.
Main outcome measure: Costs from a health service perspective and outcomes measured as quality-adjusted
life years (QALYs).
Results: For the base case, the incremental cost-effectiveness ratio of primary angioplasty was £9241 for each
additional QALY, with a probability of being cost effective of 0.90 for a cost-effectiveness threshold of £20 000.
Results were sensitive to variations in the additional time required to initiate treatment with primary angioplasty.
Conclusions: Primary angioplasty is cost effective for the treatment of AMI on the basis of threshold cost-
effectiveness values used in the NHS and subject to a delay of up to about 80 minutes. These findings are
mainly explained by the superior mortality benefit and the prevention of non-fatal outcomes associated with
primary angioplasty for delays of up to this length.
E
ffective and cost-effective management of coronary heart
disease in the UK is an NHS priority. In particular, the
timely and efficient management of acute myocardial
infarction (AMI) comprises the cornerstone of the Coronary
Heart Disease National Service Framework.1 Although the
management of AMI has improved in the UK, with an
associated 16% reduction in mortality between 1999 and
20012 reducing the gap in death rates between this country
and others in Europe,3 4 many of these deaths are still
considered to be potentially preventable.
Thrombolysis remains the predominant reperfusion strategy
for ST-segment elevation myocardial infarction in the UK, but
its use has limitations. In particular, normal coronary flow is
restored in only 25–50% of patients, depending on the choice of
thrombolytic drug.5 The increased use of primary angioplasty
has been suggested as one approach to improve further the
management of patients with AMI.6 However, the question of
whether primary angioplasty should become the first-line
treatment in the UK is still the subject of considerable debate.7 8
The Department of Health and the British Cardiac Society
have recently set up the National Infarct Angioplasty Project
(NIAP), a study to assess the feasibility of implementing a
national primary angioplasty service in 10 NHS pilot centres
across England.3 9 Apart from the logistic and economic
implications derived from any structural change in healthcare
provision, one possible reason for the limited use of primary
angioplasty in the UK NHS is the lack of evidence about its cost
effectiveness: no studies have been published relating to UK
practice and expressing outcomes as quality-adjusted life years
(QALYs), which facilitate comparison with other uses of health
service resources. Our aim was to develop a UK-specific cost-
effectiveness model of primary angioplasty compared with
thrombolysis on the basis of existing evidence.
METHODS
Overview
A probabilistic decision analytic model was constructed. A
systematic review was conducted to update the most compre-
hensive meta-analysis in this area,10 and Bayesian statistical
methods were used to synthesise the effectiveness evidence
from 22 randomised control trials.11 The model was developed
as a comprehensive decision analysis,12 13 where the individual
components of the decision modelling were dealt with
simultaneously and evaluated using a Markov Chain Monte
Carlo simulation implemented in the specialist software
WinBUGS.14
QALYs were used as the measure of health outcome. The
structure of the decision analytic model and its underlying
assumptions were developed in discussion with a group of
clinical advisors, all experienced consultant cardiologists from
the UK. The model considered the costs from the perspective of
the NHS, using 2003–4 prices, with costs and benefits
discounted at 3.5% a year.15 Details of the updated systematic
review and evidence synthesis are presented in a companion
paper to this.11 Full technical details of all methods can be
found in a technical report (available at http://heart.bmj.com/
supplemental).
Model structure
The decision model comprised two main elements: a decision
tree that captured the short-term events and costs associated
Abbreviations: AMI, acute myocardial infarction; CrI, credible interval;
GPAs, glycoprotein IIb/IIIa antagonists; ICER, incremental cost-
effectiveness ratio; MI, myocardial infarction; NHAR, Nottingham Heart
Attack Registry; NIAP, National Infarct Angioplasty Project; OR, odds ratio;
QALYs, quality-adjusted life years
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with the management of AMI using either thrombolysis or
primary angioplasty up to 6 months after an initial AMI
episode; and a long-term Markov model,16 which extrapolated
the analysis to a lifetime time horizon using an annual cycle.
Figure 1 provides a schematic diagram of the model structure.
More information about the model and a detailed diagram-
matic representation are provided in the technical report.17
Event rates with thrombolysis (referred to as ‘‘baseline’’
event rates) were multiplied by the pooled odds ratios (ORs)
estimated from the evidence synthesis to quantify the absolute
effect of primary angioplasty. The possibility of needing a
further revascularisation was also modelled. The short-term
model was used to determine, for each treatment, the costs
incurred during the initial 6 months after treatment. In
addition, it established the proportions of patients that entered
the different health states of the long-term extrapolation
model: death, alive without further events (ischaemic heart
disease state (IHD)), repeated non-fatal myocardial infarction
(MI) and non-fatal stroke. The long-term extrapolation
provided an estimate of lifetime costs and QALYs conditional
on surviving the first 6 months.
Model inputs
Clinical effectiveness
Table 1 presents the clinical effectiveness inputs used to inform
the cost-effectiveness model. Bayesian evidence synthesis was
used to inform the clinical effectiveness measures for the short-
term model, based on an average of all streptokinase and fibrin-
specific trials.11 Outcomes were estimated as a function of the
additional time delay associated with primary angioplasty
compared with thrombolysis defined as the mean difference
between time-to-balloon in primary angioplasty and time-to-
needle in thrombolysis (mean (SE) 54.3 (2.2) minutes).
The base-case analysis establishes the cost effectiveness of
primary angioplasty on the assumption that the average patient
is treated as in the randomised trials included in the meta-
analysis, and in centres that have the necessary infrastructure.
As a result, the angioplasty-related time delay applied in the
base-case analysis is based on the average figure reported across
the trials (54.3 minutes). A series of sensitivity analyses were
also undertaken to explore the impact of variation in the
estimate of time delay on the cost-effectiveness results.
Separate analyses were undertaken for delays of 30, 60 and
90 minutes. Table 1 also shows the pooled odds ratios applied
at these different time delays.
Table 2 summarises the main input variables and sources
applied in the cost-effectiveness model. The various compo-
nents are described below.
Resource use and costs during the short-term period
(6 months)
The resources considered include those associated with the initial
interventions (eg, drug acquisition costs, procedure costs and
associated hospital length of stay) and subsequent events
occurring over the following 6 months, such as further revascu-
larisations and major clinical events (either repeat MI or stroke).
For the base-case analysis, we used national statistics on the
average length of hospital stay for patients with AMI based on
Hospital Episode Statistics.18 Hence, in the absence of reliable data
with which to quantify the potential impact of primary
angioplasty on the length of the initial hospitalisation, we applied
a conservative approach by assuming that primary angioplasty has
no impact on the duration of hospitalisation (ie, we assumed a
mean length of stay of 10 days for each strategy). A separate
sensitivity analysis was also conducted17 using estimates from a
sample of 80 patients from Hammersmith and Charing Cross
Hospital, in order to assess the implications of a shorter length of
stay with primary angioplasty than with thrombolysis (Morgan K,
personal communication, 2005).
We also applied a conservative assumption about resource
use and costs for all consumables and adjunctive drugs used
with primary angioplasty. The base-case analysis assumed that
all patients receiving primary angioplasty would receive an
angiogram, adjunctive glycoprotein IIb/IIIa antagonists (GPAs)
and stents during the initial procedure, although, in reality, the
use of these adjunctive treatments is likely to vary between
different hospitals. Reflecting their use in the trials, the unit
cost of bare metal stents was used. Drug costs were taken from
the British National Formulary,19 based on licensed dosages.
Other unit costs were obtained from NHS reference costs20 and
published literature.21 22
Long-term event rates and costs
The long-term implications of two short-term (‘‘prognostic’’)
events were modelled over the long term: non-fatal MIs and non-
fatal strokes. In the absence of long-term trial evidence on the
prognosis of these patients after primary angioplasty or thrombo-
lysis, UK registry data were used to calculate long-term event rates
and associated costs. This ‘‘extrapolation modelling’’ assumed no
Figure 1 Overview of the model structure. IHD, ischaemic heart disease;
MI, myocardial infarction; RCTs, randomised controlled trials.
Table 1 Clinical effectiveness measures based on the
evidence synthesis results11 17
Base-case
value Low CrI High CrI
Probability of an event with thrombolysis
Death 0.07 0.05 0.11
Non-fatal reinfarction 0.06 0.04 0.10
Non-fatal stroke 0.02 0.01 0.06
Odds ratios—primary angioplasty effect
Average time delay (54 min)
Death 0.70 0.42 1.18
Non-fatal reinfarction 0.33 0.20 0.67
Non-fatal stroke 0.26 0.08 0.72
30 Minutes’ delay
Death 0.54 0.29 0.92
Non-fatal reinfarction 0.30 0.14 0.59
Non-fatal stroke 0.47 0.05 0.69
60 Minutes’ delay
Death 0.77 0.44 1.29
Non-fatal reinfarction 0.39 0.21 0.72
Non-fatal stroke 0.56 0.09 0.75
90 Minutes’ delay
Death 1.15 0.49 2.36
Non-fatal reinfarction 0.55 0.29 1.27
Non-fatal stroke 0.79 0.08 1.43
Results are posterior mean distributions and 95% credible interval (CrI).
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continued treatment effect difference between thrombolysis and
angioplasty beyond 6 months. The Nottingham Heart Attack
Registry (NHAR)23 was used to estimate resource use and
transition probabilities for the long-term model. NHAR was
selected because extensive follow-up data had been collected (5-
years’ follow-up) and provided detailed information on both the
frequency and timing of recurrent events as well as resource
utilisation. Transition probabilities were calculated from the
NHAR data using survival analysis techniques. Although non-
cardiac mortality was recorded in the NHAR, the probability of
non-cardiac mortality was based on UK life tables owing to the
small number of these events.2
Quality adjustment
To estimate QALYs, it is necessary to quality adjust the period of
time the average patient is alive within the model using an
appropriate utility or preference score. In the absence of utility
data from the trials and the NHAR, external estimates of utility
data were sought in order to differentiate between the health
status of patients according to the different states of the model.
A literature review was undertaken to obtain estimates of
utilities for the different long-term health states. A single utility
score for patients with a stroke was applied, which was
weighted by the probability that this event was disabling or
not.24
Table 2 Summary of other variables associated with the base-case model
Variables
Base-case
value Low CrI High CrI Distribution Source
Probabilities of further revascularisations
Primary angioplasty
Repeated angioplasty 0.054 – – Beta (a= 19, b= 319) Systematic review11 17
CABG 0.054 – – Beta (a= 18, b= 290) Systematic review11 17
Thrombolysis
Angioplasty (rescue and routine) 0.281 – – Beta (a= 27, b= 69) Systematic review11 17
CABG 0.071 – – Beta (a= 18, b= 222) Systematic review11 17
Transition probabilities*
From IHD state to non-fatal event (year 1) 0.059 0.041 0.077 Log normal NHAR23
From IHD to non-fatal event (>2 years) 0.027 0.019 0.036 Log normal NHAR23
From IHD to CV death (year 1) 0.038 0.024 0.055 Log normal NHAR23
From IHD to CV death (>2 years) 0.032 0.023 0.041 Log normal NHAR23
From non-fatal event to CV death (year 1) 0.260 0.180 0.352 Log normal NHAR23
From non-fatal event to CV death (>2 years) 0.048 0.021 0.084 Log normal NHAR23
Recurrent non-fatal event in the MI state 0.087 0.049 0.134 Posterior distribution NHAR23
Recurrent non-fatal event in the stroke state 0.038 0.017 0.182 Posterior distribution NHAR23
Recurrent stroke 0.498 0.095 0.906 Posterior distribution NHAR23
Hospital length of stay after acute MI (days) 10 – – Fixed HES18
Unit costs (£) treatment initial acute MI episode`
Cardiac ward 173 – – Fixed 20
Angiography (procedure) 727 – – Fixed 21
Primary angioplasty (procedure) 1614 – – Fixed 21
Guidewire 71 – – Fixed 21
Bare metal stent 370 – – Fixed 22
Guiding catheter 42 – – Fixed 21
Balloon 231 – – Fixed 21
Abciximab 1042 – – Fixed 22
Streptokinase 89.72 – – Fixed 22
Alteplase 600 – – Fixed 22
Unit costs (£) events after initial episode`
Acute MI (episode) 1055 – – Fixed 20
Primary angioplasty (procedure) 2984 – – Fixed 20
CABG (procedure) 6450 – – Fixed 29
Long-term costs associated with health states*1
IHD state 431 99 1209 Posterior distribution Technical report17
MI state (year 1) 1964 1368 3150 Posterior distribution Technical report17
After MI state (>2 years) 91 375 1188 Posterior distribution Technical report17
Stroke state (year 1) 8786 8244 9395 Posterior distribution Technical report17
After stroke (>2 years) 2318 1826 2933 Posterior distribution Technical report17
Utilities associated with health states
MI state (year 1) 0.683 – – Beta (a= 624, b= 289) Measured 6 months after
hospital discharge25
After MI state (>2 years) 0.718 – – Beta (a= 564, b= 222) Measured 12 months after
hospital discharge25
Non-disabled stroke 0.740 – – Beta (a= 219, b= 78) 26
Disabled stroke 0.380 – – Beta (a= 43, b= 70) 26
Combined stroke 0.612 – – – 26
CABG, coronary artery bypass grafting; CrI, credible interval; CV, cardiovascular; IHD, ischaemic heart disease; MI, myocardial infarction.
*Mean and 95% CrI reported.
Hazard rates obtained from survival analysis, converted to probabilities.
`Price year 2003–4; all costs updated using HCHS27 price index 2004.
1All annual costs adjusted by average number of days spent in each state based on NHAR dataset.
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Analytical methods
The model was run probabilistically and the uncertainty in the
individual measures was fully characterised using the prob-
ability distributions summarised in table 2. The results of the
model are presented in two ways. First, mean lifetime costs and
QALYs for both strategies are reported and their cost effective-
ness presented using incremental cost-effectiveness ratios
(ICERs).28 Second, decision uncertainty is presented as the
probability that each intervention is considered the more cost
effective for a given cost-effectiveness threshold.
The following analyses are undertaken. First, the impact on
the cost-effectiveness results of a range of alternative time
delays (30, 60 and 90 minutes) is explored. Second, the base-
case assumption of equal durations of initial hospital stays with
both treatments is relaxed and the impact of differential
lengths of initial hospitalisation stay (5.8 days (SE 1.6) for
primary angioplasty; 12.1 (SE 2.9) for thrombolysis) (Morgan
K, personal communication, 2005) assessed. Third, the implica-
tions of higher costs for primary angioplasty because of the
need to invest in new infrastructure in hospitals without
existing facilities are explored.
RESULTS
Clinical effectiveness
The full clinical results from the evidence synthesis have been
published.11 Briefly, the results showed that for the average
time delay (54 minutes) the mean event probabilities were
lower for primary angioplasty for all outcomes. Mortality
within 6 months was 5.5% after angioplasty and 7.7% after
thrombolysis (OR = 0.70; 95% credible interval (CrI) 0.42 to
1.18). For non-fatal re-infarction, the OR was 0.33 (95% CrI
0.20 to 0.67); and for non-fatal stroke 0.26 (95% CrI 0.08 to
0.72). For all outcomes, the benefit of angioplasty decreased
with longer treatment initiation delay (table 1).
Cost effectiveness: base-case analysis
Table 3 presents the base-case results. Primary angioplasty is
the most expensive option (mean lifetime costs £12 760 vs
£10 080), but it was also associated with a mean lifetime QALY
gain of 0.29 (7.12 vs 6.83). The ICER associated with primary
angioplasty compared with thrombolysis was £9241 for each
additional QALY, hence primary angioplasty will be the optimal
treatment provided that the NHS is prepared to pay at least this
amount. The probability that primary angioplasty is cost
effective is around 0.55 for a cost-effectiveness threshold of
£10 000, increasing to almost 1 for a threshold of £30 000 per
QALY.
Cost effectiveness: alternative scenarios
Reducing the time delay to 30 minutes improves the estimate of
cost effectiveness, with a reduction of the ICER to £6850 per
QALY. Furthermore, the probability that this strategy is cost
effective is 0.82 at a threshold of £10 000, increasing to close to
1 for a threshold of £20 000 and above. These results are
explained by a higher mortality benefit at 30 minutes
(OR = 0.54; 95% CrI 0.29 to 0.92) and a slightly higher
prevention of non-fatal reinfarction than those estimated based
on the average time delay.
As expected, results at 60 minutes were similar to those for
average time delay, but increasing the time delay up to
90 minutes resulted in a sevenfold increase in the base-case
ICER (£64 750 per QALY) and a substantial reduction in the
Table 3 Cost-effectiveness results
Time delay Strategy
Mean costs
(£) Mean QALYs
ICER
(£)
Probability of being cost effective for
threshold of:
£10 000 £20 000 £30 000
Base-case analysis
Average delay (54 min) Primary angioplasty 12 760 7.12 9 241 0.55 0.90 0.95
Thrombolysis 10 080 6.83 – 0.45 0.10 0.05
Time delays of:
30 Minutes Primary angioplasty 12 820 7.23 6 850 0.82 0.98 0.99
Thrombolysis 10 080 6.83 – 0.18 0.02 0.01
60 Minutes Primary angioplasty 12 750 7.09 10 269 0.43 0.83 0.91
Thrombolysis 10 080 6.83 – 0.57 0.17 0.09
90 Minutes Primary angioplasty 12 670 6.87 64 750 0.13 0.36 0.45
Thrombolysis 10 080 6.83 – 0.87 0.64 0.55
Differential length of hospital stay*
Average delay (54 min) Primary angioplasty 12 030 7.12 5 448 0.82 0.95 0.97
Thrombolysis 10 450 6.83 – 0.18 0.05 0.03
30 Minutes Primary angioplasty 12 085 7.23 4 087 0.95 0.99 0.99
Thrombolysis 10 450 6.83 – 0.05 0.01 0.01
60 Minutes Primary angioplasty 12 020 7.09 6 038 0.75 0.91 0.99
Thrombolysis 10 450 6.83 – 0.25 0.09 0.01
90 Minutes Primary angioplasty 11 940 6.87 37 250 0.32 0.47 0.52
Thrombolysis 10 450 6.83 – 0.68 0.53 0.48
ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years.
*Using an estimate of 5.8 days (SE 1.6) for primary angioplasty and 12.1 days (SE 2.9) for thrombolysis (Morgan K, personal communication, 2005).
Figure 2 Threshold analysis: impact of varying additional investment costs
per patient compared with the base-case analysis for different time delay
scenarios. QALY, quality-adjusted life year.
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probability that primary angioplasty was considered cost
effective at conventional thresholds considered to represent
value for money in the NHS.15 This is explained by the fact that
no additional mortality benefit is apparent with primary
angioplasty for 90 minutes’ delay in starting treatment.
The alternative setting with lower length of initial hospita-
lisation with primary angioplasty (5.76 days compared with
12.12 days for the thrombolytic strategy) showed an improve-
ment in the estimate of cost effectiveness, with a reduction of
the ICER for all time delays. In this setting, even for a delay up
to 90 minutes, primary angioplasty was the optimal strategy for
a threshold of £30 000.
The cost-effectiveness results presented here are based on the
assumption that centres already have the necessary infrastruc-
ture to provide primary angioplasty. Figure 2 presents a
threshold analysis showing the impact of additional investment
costs in new facilities for primary angioplasty that may be
necessary in some centres. This represents an ‘‘up front’’ capital
investment allocated per patient for primary angioplasty. This
demonstrates that, in cases where the additional investment
costs are up to the equivalent of £9000 per patient and when
the additional time delay associated with primary angioplasty
over thrombolysis is no higher than 60 minutes, the cost
effectiveness of primary angioplasty would be in the region of
£20 000 to £40 000 per QALY. In those cases where additional
investment cost per patient is higher than £9000, thrombolysis
is the optimal strategy.
DISCUSSION
Several studies have looked at the economics of primary
angioplasty.29–31 For decision making in the UK NHS, however,
a cost-effectiveness analysis should have some key features.15
These include the incorporation of all relevant trial evidence on
clinical effects, the expression of outcomes as QALYs for
comparison across clinical areas and the use of UK costs. Some
studies have been based on systematic reviews of clinical
effects,29 two used QALYs30 31 and one UK costs,29 but we are not
aware of any existing study with all these features.
Despite hitherto limited evidence for its cost effectiveness,
widening the use of primary angioplasty in the UK NHS is
already being considered. Findings from the NIAP project, due
in 2008, will inform policy on the provision of primary
angioplasty as a first treatment for patients who have a heart
attack.3 9 Results from the analysis presented here suggest that
primary angioplasty is cost effective based on the cost-
effectiveness thresholds used by the National Institute for
Health and Clinical Excellence (£20 000 to £30 000 per
additional QALY15 32). This conclusion, however, is sensitive to
the additional time delay associated with primary angioplasty.
The results from the different scenarios suggest that primary
angioplasty may not be cost effective for an additional delay
somewhere within the region of 60 to 90 minutes. An
additional analysis was undertaken to identify the time at
which primary angioplasty no longer seems to be cost effective
compared with thrombolysis. At a cost-effectiveness threshold
of £20 000 per QALY, primary angioplasty appears cost effective
for delays of less than 79 minutes (and 84.5 minutes at £30 000
per QALY). The cost effectiveness of primary angioplasty may
also be sensitive to the set-up costs of the service.
The comprehensive decision modelling methods used in the
analyses presented here allow both evidence synthesis and
decision analytical models to be combined within a single
coherent modelling framework, which not only allows all
sources of uncertainty to be appropriately propagated through-
out the analysis, and consequently included in the overall cost-
effectiveness estimates, but also allows appropriate considera-
tion of the correlation induced when the same evidence source
contributes to multiple components of the decision model.12 The
Bayesian approach also enables the inclusion of complex data
structures and networks of evidence without the need to make
distributional assumptions about model inputs.12 13 33
In addition to handling the uncertainty in the evidence, it is
also important to reflect variation—for example, in clinical
context and practice, resource use and costs between hospitals.
Analyses of various scenarios have been used here to assess the
implications of additional time delay in providing angioplasty,
differential lengths of hospital stay and additional investment
cost in new facilities. These show the likely boundaries of the
cost effectiveness of primary angioplasty. Each input into the
analysis is estimated with uncertainty but, using probabilistic
methods, the analysis shows that, for most settings, primary
angioplasty has the highest probability of being cost effective
even at lower cost-effectiveness thresholds. However, the
remaining decision uncertainty may indicate that further
primary research into the costs and effects of primary
angioplasty would be good value.17
As is often the case in evaluating medical interventions,
technologies advance more rapidly than the evidence base.
Since the majority of the trials informing this analysis were
undertaken, medical practice for the delivery of thrombolysis
and primary angioplasty has changed. For example, a large
proportion of patients undergoing primary angioplasty today
will have stents and GPAs as adjuvant drugs. Where possible,
assumptions have been used which are conservative with
respect to primary angioplasty (ie, tend to underestimate its
cost effectiveness). For example, the use of stents and GPAs has
been included as part of the cost of the primary angioplasty
procedure, although only a proportion of patients in the most
recent trials included in our review used them, and thus their
influence on the overall estimated effectiveness was low. A
sensitivity analysis (not reported here) has been undertaken
using the price of streptokinase and including trials using only
fibrin-specific thrombolytic agents, with no major changes in
the results.17 Moreover, an increasing proportion of patients
undergoing thrombolysis will later receive ‘‘rescue’’ percuta-
neous coronary intervention to achieve reperfusion or revascu-
larisation before discharge. This would probably affect the cost
and effectiveness of a strategy of initial thrombolysis. This is
also likely to be true for a large proportion of patients receiving
pre-hospital thrombolysis.34
The lack of individual patient data from the trials precludes
an analysis of how the relative effectiveness and cost effective-
ness of angioplasty varies between subgroups of patients
defined by their clinical and sociodemographic factors, so cost
effectiveness is presented for the ‘‘average’’ patient reflected in
the evidence. Our analysis should not be used to determine
whether an individual patient should or should not receive
primary angioplasty, but may reflect how cost effective a
primary angioplasty service might be, depending on mean call-
to-balloon times for the population being served. Furthermore,
it has to be recognised that patients in routine practice are likely
to show some differences from those included in trials. There is
some conflicting evidence on whether primary angioplasty will
be more or less effective in routine practice.35 36
Some limitations to the analysis should be noted. First, the
time between patients contacting emergency services and
receiving thrombolysis is a predictor of efficacy.37 38 However,
this likely source of variability in cost effectiveness could not be
explicitly included in the analysis owing to inconsistent
reporting in the trials. Therefore, results presented here
represent average time-to-needle (54.3 minutes), which is
similar to the mean time-to-needle in the UK of 67 minutes
(personal communication, Dr John Birkhead, UK Myocardial
Infarction National Audit Project). Second, given that our
1242 Bravo Vergel, Palmer, Asseburg, et al
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systematic review was an update of a previously published
meta-analysis,10 neither the effect of publication bias nor study
quality were formally assessed. Third, ideally the analysis
would have compared the full range of reperfusion strategies,
including different thrombolytic agents, alternative modes of
administration and the use of rescue or facilitated angio-
plasty.39 40 These analyses represent significant extensions of the
work presented here.
In conclusion, the analysis suggests that primary angioplasty
is cost effective for the treatment of AMI, on the basis of
threshold values used in the NHS, for a time delay of up to
about 80 minutes.
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